Application of hemofiltercytological analysis shows its ample opportunities in assessment of polychemotherapy completeness and quality through the study of drug pathomorphosis. The objective of the study was development and studying of the clinical relevance of hemofiltercytological venous blood test as completeness and quality control of patients with colorectal cancer adjuvant chemotherapy. 35 of 39 tested cancer patients who underwent radical surgery for colorectal cancer of different localization, including cases of locally advanced stage had cancer cells in peripheral blood. Thus, the percentage of patients who had atypical cells in venous blood in postoperative period was 89.7. Adjuvant chemotherapy was offered to all 35 patients with diagnosed carcinemia and after their consent it was held in modes FOLFOX-4 and XELOX. Evaluation of anticancer drugs therapeutic action is traditionally carried out using the criteria of objective and subjective effects. The criterion of objective effect during chemotherapy of solid tumors is reduction of tumor and metastases and the criterion of subjective one is well-being of a patient. In addition, it is important to notice the highest drug resistance observed at rectum cancer, because there is a predominance of smaller stages I to II of drug pathomorphosis (9 to 7) over greater stages III-IV (7 to 1) among these cancer patients. Consequently, hemofiltercytological blood test provides a real opportunity to assess the effect of polychemotherapy and to solve the problem of chemotherapeutic treatment courses number necessary to stabilize the cancer process.
Key words: Calibrated filter, hemofiltercytological blood test, carcinemia, microscreening.
Copyright © 2021 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0